PBT collapsed 84% as second half slid into NPAT loss

EBITDA fell 39.4% to $31.4m, PBT dropped 84.0% to $3.8m, and NPAT fell 84.7% to $2.6m. The shape through the year matters: with 1H24 NPAT at $5.3m, the implied second half was a $2.7m loss, and second-half EBITDA of $10.2m was less than half the first-half run-rate.

Operating cash flow fell 57.0% to $42.2m but still printed 134.5% of EBITDA, supported by a $36.3m operating working-capital release (inventory down $17.8m, trade debtors down $14.2m). Cash rose to $8.7m and the company carries no bank borrowings. The final dividend was halved to 2 cents, taking the full-year dividend to 6 cents from 8 cents in FY23.

The full-year NPAT of $2.6m is entirely first-half; the implied second-half NPAT is a $2.7m loss, and second-half EBITDA halved versus the first half. Management's reference to a further $5m cost-out programme implies the cost base remains too heavy for current volumes. The exit run-rate matters more than the headline FY24 average for assessing where FY25 starts.

Dividend has run well ahead of earnings. The 6c full-year dividend is 375.0% of NPAT, up from 77.7% in FY23. It remains covered by pre-lease free cash flow ($32.7m at a 30.3% payout), but that FCF was generated by shrinking working capital. If volumes recover, working capital will reabsorb cash and earnings-based dividend coverage becomes the binding constraint.

Operating leverage cuts both ways. A 18.7% revenue decline produced a 39.4% EBITDA fall and an 84.0% PBT fall. Distribution, at 57.8% of revenue, saw segment result collapse from $21.2m to $2.2m even as its disclosed gross margin held at 21.0%, so fixed-cost absorption rather than pricing is the driver. Recovery is therefore geared to volume returning, not margin repair.

Management commentary references a further $5m cost-out programme and balance-sheet optionality for organic and acquisitive growth, but does not supply a numeric path. The release supports a thesis that earnings are near a cyclical low and the balance sheet ($8.7m cash, no debt) gives time to wait, but it does not underwrite the timing of a recovery.

The shape that matters for FY25 is whether revenue stabilises or continues to decline. The second-half run-rate (revenue $217.4m, EBITDA $10.2m) annualised sits materially below FY24, which makes the "volumes return" framing the key assumption to test at HY25.

The $36.3m operating working-capital release is a one-time benefit from shrinking the balance sheet to match weaker demand. Strip the release and operating cash sits well below EBITDA; the underlying earnings-to-cash relationship is weakening, not just normalising.

The segment and working-capital detail reinforces that this is not a clean cyclical floor. Inventory days extended from 86.3 to 92.5 despite the $17.8m absolute reduction, meaning the inventory release lagged the revenue fall. A demand recovery would reabsorb working capital before it lifts reported cash. ROE of 1.3% versus 8.2% prior confirms the equity base is currently earning a low single-digit return, and recovery must come from the income statement rather than further balance-sheet shrinkage. Capex stepped up from $6.2m to $9.5m (2.0% of revenue), so the lower investment year is also behind the business.

This briefing cannot assess current-quarter trading momentum or the phasing of the cost-out programme without further management disclosure.